default author photo

Raches Ella

Bharat Biotech International Ltd

India

  • Bharat Biotech International Ltd

SCHOLARLY PAPERS

2

DOWNLOADS

220

TOTAL CITATIONS

15

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152: A Phase 1, Double-Blind, Randomised Control Trial

Number of pages: 224 Posted: 11 Dec 2020
Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, Sai D. Prasad, Siddharth Reddy, Vamshi Sarangi, Brunda Ganneru, Gajanan N. Sapkal, Pragya Yadav, Priya Abraham, Samiran Panda, Nivedita Gupta, Prabhakar Reddy, Savita Verma Attri, Sanjay Kumar Rai, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Venkat Rao, Randeep Guleria and Krishna M. Ella
Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR), Nizams Institute of Medical Sciences, - Department of Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, All India Institute of Medical Sciences, Patna, Redkar Hospital, Gillurkar Hospital, Prakhar Hospital, SRM Hospital and Research Centre, Institute of Medical Sciences and SUM Hospital, All India Institute of Medical Sciences (AIIMS) - Department of Pulmonary, Critical Care and Sleep Medicine and Bharat Biotech International Ltd
Downloads 160 (467,092)
Citation 10

Abstract:

Loading...

SARS-CoV-2, COVID-19, vaccine, BBV152, inactivated vaccine, th1

2.

Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152

Number of pages: 45 Posted: 25 Nov 2020
Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram, Narasimha Reddy Molugu, Sai D. Prasad, Srinivas V. Kannappa, Krishna M. Ella, Rajaram Ravikrishnan, Amit Awasthi, Jomy Jose, Panduranga Rao, Deepak Kumar, Raches Ella, Priya Abraham, Pragya Yadav, Gajanan N. Sapkal, Anita Shete, Gururaj Rao Desphande, Sreelekshmy Mohandas, Atanu Basu, Nivedita Gupta and Krishna Mohan Vadrevu
Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, RCC Labs, Government of India - Immuno-biology Lab, RCC Labs, Bharat Biotech International Ltd, Bharat Biotech International Ltd, Bharat Biotech International Ltd, National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), Indian Council of Medical Research (ICMR) and Bharat Biotech International Ltd
Downloads 60 (961,006)
Citation 5

Abstract:

Loading...

SARS-CoV-2; covid vaccine; COVID-19; covaxin; BBV152